Drug Information Update - Federal judge approves consent decree with New York dietary supplement maker

FDA Division of Drug Information: Know the Moment It Happens

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.


A federal judge in New York has signed a consent decree for permanent injunction between the United States and Mira Health Products Ltd., a dietary supplement manufacturer located in Farmingdale, New York, and Michael S. Ragno and Michael S. Ragno, Jr.

On July 26, 2013, the FDA issued a warning to consumers not to use or purchase Healthy Life Chemistry By Purity First B-50, a dietary supplement manufactured by Mira. The FDA issued this warning after receiving numerous reports of illness associated with use of the product. An FDA laboratory analysis found that the product contained two drugs that are potentially harmful anabolic steroids—methasterone, a controlled substance, and dimethazine. These ingredients were not listed on the label and should not have been in a dietary supplement because they are illegal drugs and not dietary ingredients.

For more information, please visit: Mira


This is an automated message delivery system.  Replying to this message will not reach DDI staff.  If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday.  You can also email us at druginfo@fda.hhs.gov.


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery